Specialized Formulation Expertise LATITUDE Pharmaceuticals specializes in developing innovative formulations for insoluble and unstable drug molecules, creating proprietary drug delivery technologies and license-ready formulations. This positions them as a strategic partner for biotech and pharmaceutical companies seeking advanced formulation solutions and intellectual property development.

Growing Industry Presence Operating as a CDMO with a focus on formulation and GMP manufacturing, LATITUDE serves a niche market within the broader pharmaceutical manufacturing sector, which is characterized by ongoing demand for complex drug formulations and novel delivery technologies in the biotech and pharma industries.

Acquisition Momentum LATITUDE was acquired by BioVie Inc in 2016, indicating interest from larger biotech entities and potential for strategic partnerships, licensing opportunities, or collaborative development programs that can enhance sales prospects and expand market reach.

Mid-Size Revenue opportunity With an estimated revenue range of 10 to 25 million dollars, LATITUDE presents an attractive target for scaled business development efforts aimed at expanding contracts, increasing formulation projects, and broadening client base within the thriving pharmaceutical CDMO segment.

Competitive Positioning LATITUDE competes with other specialized contract manufacturers like Vetter, Cambrex, and Recipharm, making it vital to highlight unique formulation capabilities, advanced proprietary technologies, and flexible manufacturing services to differentiate and capture more market share.